Abstract
In this issue of Blood, Oliveri and colleagues and Magro and colleagues report pilot trials using imatinib for steroid refractory sclerotic cGVHD, showing response rates of 79% and 50%.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 498-499 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 114 |
| Issue number | 3 |
| DOIs |
|
| State | Published - 2009 |
| Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology